Nexavar's domination of HCC set to continue
This article was originally published in Scrip
Executive Summary
Nexavar will remain unchallenged in the foreseeable future as the first-line standard-of-care therapy for advanced hepatocellular cancer (HCC) as there are no potential first-line competitors in the late-stage development pipeline. In addition, Nexavar's commercial potential in the adjuvant setting, where it is currently in Phase III testing, is greater than other pipeline therapies, according to analysis from Datamonitor Healthcare.